If You're Struggling to Find Octreotide, You're Not Alone

You got your prescription, called the pharmacy, and heard the words no patient wants to hear: "We don't have it in stock." If you rely on Octreotide for acromegaly, carcinoid syndrome, or another condition, not being able to fill your prescription can feel overwhelming — even scary.

The truth is, Octreotide has been one of the harder specialty medications to find over the past few years. Supply disruptions, limited manufacturers, and complicated production processes have all contributed to ongoing availability problems. In this article, we'll explain exactly why Octreotide is so hard to find and what steps you can take right now to get the medication you need.

What Is Octreotide?

Octreotide is a synthetic version of a natural hormone called somatostatin. It belongs to a class of drugs known as somatostatin analogs. Your body naturally produces somatostatin to regulate hormone release, but Octreotide is a much more potent and longer-lasting version.

Doctors prescribe Octreotide to treat several serious conditions:

• Acromegaly — a condition where the body produces too much growth hormone, usually due to a pituitary tumor
• Carcinoid syndrome — severe diarrhea and flushing caused by neuroendocrine tumors
• VIPomas — tumors that produce too much vasoactive intestinal peptide, causing profuse watery diarrhea

Octreotide is available under several brand names including Sandostatin, Sandostatin LAR Depot (the long-acting injection given every 4 weeks), Bynfezia Pen, and Mycapssa (the only oral form). For more details about what Octreotide is and how it works, check out our in-depth guide.

Why Is Octreotide So Hard to Find in 2026?

There isn't one single reason Octreotide is hard to find. It's a combination of factors that have created a perfect storm of supply issues. Here are the main ones:

1. Manufacturing Complexity

Octreotide — especially the long-acting release (LAR) formulation — is extremely difficult to manufacture. The LAR version uses a microsphere technology where the drug is encapsulated in tiny biodegradable polymer spheres that slowly release the medication over four weeks. This process requires specialized equipment and tight quality controls. When something goes wrong in production, it can take months to fix.

Unlike a simple pill that can be stamped out by dozens of manufacturers, Octreotide LAR requires a level of manufacturing precision that very few companies in the world can achieve.

2. Limited Number of Manufacturers

For years, Novartis was essentially the only company making the LAR formulation (as Sandostatin LAR Depot). While Teva Pharmaceuticals received FDA approval for generic Octreotide LAR in October 2024, ramping up production to meet full demand takes time. Teva's 20 mg kit was on back order through late 2025, showing that even with a new generic, supply hasn't caught up with demand.

For the immediate-release injection, there are more options — companies like Avet, Fresenius Kabi, Hikma, and Sagent all produce generic versions. But even these manufacturers have experienced intermittent shortages due to manufacturing delays.

3. Increased Demand

Octreotide use has expanded beyond its original indications. As more research supports its use in gastroenteropancreatic neuroendocrine tumors, hepatorenal syndrome, variceal bleeding, and other conditions, demand has steadily increased. The patient population that needs this drug has grown, but manufacturing capacity hasn't kept pace.

4. Specialty Pharmacy Distribution

Unlike medications you can pick up at any corner pharmacy, Octreotide LAR is typically distributed through specialty pharmacies. This means fewer locations stock it, and when supply is tight, patients in certain areas may be left without access. Your neighborhood CVS or Walgreens likely doesn't carry the LAR formulation at all.

What You Can Do to Find Octreotide

The good news is you have options. Here's what you can do right now:

Use Medfinder to Check Pharmacy Availability

Medfinder helps you search for pharmacies that have Octreotide in stock near you. Instead of calling pharmacy after pharmacy, you can check availability in real time and save yourself hours of frustration. Learn more about how to check if a pharmacy has Octreotide in stock.

Ask About All Available Formulations

If you can't find Sandostatin LAR, ask your doctor about switching to:

• Generic Octreotide immediate-release injection — more widely available, though it requires multiple daily injections
• Teva's generic Octreotide LAR — the newly approved alternative to Sandostatin LAR
• Mycapssa — the oral capsule form (approved for acromegaly maintenance)

Contact Specialty Pharmacies Directly

Specialty pharmacies that focus on oncology and endocrinology medications may have better access to Octreotide supply chains. Ask your doctor's office for referrals to specialty pharmacies in your network.

Talk to Your Doctor About Alternatives

If Octreotide is unavailable for an extended period, your doctor may recommend alternative medications like Lanreotide (Somatuline Depot) or Pasireotide (Signifor). These are also somatostatin analogs that may work for your condition.

Look Into Patient Assistance Programs

Novartis offers patient support programs that can help with access and affordability. If cost is a barrier, explore coupons, discounts, and patient assistance programs for Octreotide.

Final Thoughts

Finding Octreotide in 2026 requires patience and persistence, but you don't have to navigate it alone. The supply situation is slowly improving thanks to new generic approvals and additional manufacturers entering the market. In the meantime, tools like Medfinder can help you locate pharmacies with Octreotide in stock, and your healthcare team can help you explore all available options.

Don't wait until your last dose to start looking. If you're running low on Octreotide, start searching for your next supply as early as possible. For step-by-step guidance, read our article on how to find Octreotide in stock near you.